Inclusion Criteria:

          1. Histologically proven advanced MPM, advanced peritoneal mesothelioma (for dose
             escalation cohort only) or non-squamous NSCLC (stage IIIB/IV) who have not been
             treated with prior chemotherapy or immunotherapy, except that NSCLC subjects with EGFR
             mutant or ALK positive must have had an EGFR tyrosine kinase inhibitor (TKI) or ALK
             inhibitor and progressed or been shown to be intolerant of therapy prior to enrolling
             in this trial, if such ALK inhibitor and EGFR targeted therapy are approved and
             available in the country in which patients are being enrolled OR Histologically proven
             metastatic uveal melanoma who have not been treated with prior chemotherapy (MTD
             cohort only), OR Histologically proven HCC who have failed (PD and/or side
             effects-been intolerant of) treatment with sorafenib. Failure is defined as having
             progressed radiographically on, or been intolerant to prior systemic therapy.
             Intolerance is defined as discontinuation due to an AE(s) on prior systemic therapy
             that was unacceptable to the treating physician and / or patient, with or without dose
             interruption and modification. Failure requires at least 14 days of treatment with
             sorafenib, except for a subject that has had a severe allergic reaction to sorafenib
             at any time, even less than 14 days of treatment with sorafenib and thus it would be
             imprudent to re-challenge them with that agent. Cirrhotic status of Child-Pugh grade
             A-B7 must be present. Child-Pugh status should be determined based on clinical
             findings and laboratory data during the screening period (Appendix E). Subjects on
             anti-coagulants are to receive 1 point for their INR status, as they are presumed to
             have a <1.7 baseline PT/INR.", OR Histologically proven high-grade glioma who have
             failed (PD and/or side effects) treatment with radiotherapy ± temozolomide, OR
             Sarcomatoid cancer of any line.

          2. ASS1 deficiency (defined as ≤50% ASS expression) demonstrated on tissue specimen
             (cytospin samples are acceptable) by immunohistochemistry (IHC). For subjects
             previously treated with chemotherapy, this specimen may have been obtained before that
             chemotherapy. A new tissue specimen obtained after most recent chemotherapy is not
             required. Thus ASS1 deficiency is required for entrance into the study. If tissue is
             not available to determine ASS1 deficiency, then tissue must be obtained by biopsy to
             determine ASS1 status.

          3. Measurable disease as assessed by modified RECIST for MPM and by RECIST 1.1 criteria
             for peritoneal mesothelioma, NSCLC, uveal melanoma, HCC, glioma and sarcomatoid
             carcinoma

          4. ECOG performance status of 0 - 1

          5. Predicted life expectancy of at least 12 weeks.

        Exclusion Criteria:

          1. Radiotherapy (except for palliative reasons), targeted therapy, or immunotherapy
             (except for uveal melanoma) the previous four weeks before study treatment.

          2. Ongoing toxic manifestations of previous treatments.

          3. Symptomatic brain or spinal cord metastases (patients must be stable for > 3 months
             post radiotherapy or surgery) for subjects with mesothelioma, NSCLC, uveal melanoma
             excludes subjects with HCC or glioma).

          4. Major thoracic or abdominal surgery from which the patient has not yet recovered.

          5. Serious infection requiring treatment with intravenous antibiotics at the time of
             study entrance, or an infection requiring intravenous therapy within 7 days prior to
             the first dose of study treatment.